12:00 AM
 | 
May 07, 2012
 |  BC Week In Review  |  Company News  |  Deals

H3 Biomedicine, Horizon Discovery Ltd, Eisai deal

H3 Biomedicine will use Horizon's GENESIS recombinant adeno-associated virus (rAAV)-associated genome editing technology and X-Mutant And Normal (X-MAN) human isogenic cell lines to identify and validate genetic targets for personalized cancer treatments. Horizon will...

Read the full 147 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >